Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 60505-6068
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 60505-6068). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Apotex Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure2 (Figure2)
Figure3 (Figure3)
The text is displaying a graph showing the survival probability (%) over a period of time (in months) of two chemotherapy treatments (Pemetrexed + Cisplatin and Gemcitabine + Cisplatin) based on data from a group of patients. The number of patients at risk is noted for each treatment at different points in time.*
Figure4 (Figure4)
Figure5 (Figure5)
This appears to be a table regarding patients who are at risk and their survival times. The table includes information on Pemetrexed (441 patients) and Placebo (222 patients). The "Survival Time" column has various numbers which may represent months. The rest of the text seems to be random characters and symbols, and it is not clear what they represent.*
Figure6 (Figure6)
This data appears to be a survival analysis of patients at risk who were treated with either Pemetrexed or a placebo. The number of patients in each group and the survival time in months are shown in a table. However, the text is incomplete and unclear in some places, making it difficult to interpret the results accurately.*
Figure7 (Figure7)
This is a survival curve with data for two groups of patients (one group received Pemetrexed and the other group received a Placebo). The x-axis represents time (in months) and the y-axis represents the number of patients who are alive at each time point. The numbers above the x-axis indicate the months since treatment, while the numbers on the y-axis indicate the number of patients remaining at each time point. The graph shows that patients who received Pemetrexed had higher survival rates compared to those who received Placebo.*
Figure8 (Figure8)
Figure9 (Figure9)
This is a graph showing the survival probability of patients taking Pemetrexed + Cisplatin and only Cisplatin over a period of 30 months. The X-axis represents the survival time in months while the Y-axis shows the number of patients at risk. The number of patients decreases as time goes by due to deaths or other factors. The survival probability of patients taking Pemetrexed + Cisplatin is generally higher than that of those taking only Cisplatin.*
Pemetrexed-750mg-carton (Pemetrexed 750mg Carton)
This is a description of a chemotherapy drug called Bonly Pemetrexed and Ronly Pemetrexed that comes in single-dose vials for intravenous use only. Each vial contains the equivalent of 750mg of pemetrexed disodium, which is a cytotoxic agent. The drug is manufactured by APOTEX CORPORATION. To reconstitute, 30 mL of 0% sodium chloride injection should be added to the vial. The reconstituted solution must be further diluted before use. The drug must be used within 24 hours of reconstitution. The drug should be stored at 25°C (77°F), with excursions permitted from 15°C to 30°C (59°F to 86°F).*
Pemetrexed-750mg-vial (Pemetrexed 750mg Vial)
This is a description of a chemotherapy drug called Befonly, which contains pemetrexed disodium. Each vial has 750mg of pemetrexed and mannitol. The drug is only for intravenous use and is a cytotoxic agent. The drug is manufactured by Apotex Corp. Hydrochloric acid and sodium hydroxide might be added to adjust pH. It needs to be stored at room temperature or refrigerated, and the drug is a single-dose vial. There is a barcode on the label.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.